2414 Results for "

decrease

" in MedChemExpress (MCE) Product Catalog:
Products (2414)

2414 Results for "decrease" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-14744
CAS No.: 103129-82-4
Purity:  98.53%
Synonyms: (S)-Amlodipine; Levoamlodipine
Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-157189
CAS No.: 898211-21-7
Purity:  99.72%
Synonyms: GPR132 antagonist 1
Target:  

G2A (GPR132)

Research Areas:  

Metabolic Disease

NOX-6-18 (GPR132 antagonist 1) is a GPR132 antagonist with an IC50 of 15.17 nM against the human target. NOX-6-18 inhibits GPR132 activation via interaction with non-conserved residues, blocks activities induced by endogenous agonists and 9 (S)-HODE, and exhibits selectivity for other fatty acid-binding GPCRs. NOX-6-18 regulates macrophage reprogramming, alleviates inflammatory responses, downregulates inflammatory markers and signaling pathways, and reduces the degree of hepatic steatosis and hepatic triglyceride levels. NOX-6-18 regulates metabolic homeostasis, reduces weight gain, enhances glucose metabolism, improves glucose tolerance, decreases fasting blood glucose and insulin levels, and partially reverses reductions in energy expenditure and respiratory quotient. NOX-6-18 can be used in the research of type 2 diabetes .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N3001
CAS No.: 957-66-4
Isolinderalactone is a sesquiterpene that exhibits anti-cancer, anti-inflammatory, and neuroprotective effects. Isolinderalactone inhibits VEGF expression and tyrosine phosphorylation of VEGFR2. Isolinderalactone decreases viability and induces apoptosis in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells. Isolinderalactone induces G2/M phase cell cycle arrest, ROS generation, pJNK/p38 MAPK activation, in colorectal cancer (CRC) cells. Isolinderalactone blocks LPS (HY-D1056)-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages. Isolinderalactone improves cognitive dysfunction in APP/PS1 mice. Isolinderalactone can be used for the study of Glioblastoma multiforme (GBM), colorectal cancer, Alzheimer’s disease and acute lung injury .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-14744A
CAS No.: 150566-71-5
Purity:  99.84%
Synonyms: (S)-Amlodipine besylate; Levoamlodipine besylate
Target:  

Calcium Channel MMP

Research Areas:  

Cardiovascular Disease

Levamlodipine ((S)-Amlodipine; Levoamlodipin) besylate is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine besylate significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine besylate not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine besylate exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine besylate may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine besylate can be used in research related to hypertension and atherosclerosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0541
CAS No.: 69884-00-0
Synonyms: Ginsenoside A1
Pseudoginsenoside F11 is an orally active neuroprotective agent. Pseudoginsenoside F11 reduces the expression of β-amyloid precursor protein, inhibits the production of Aβ1-40, downregulates the expression of JNK2, p53 and activated Caspase 3, and restores the activities of SOD and Glutathione peroxidase. Pseudoginsenoside F11 inhibits the excessive activation of μ-Calpain and restores the level of neuronal Nitric oxide synthase. Pseudoginsenoside F11 reduces infarct volume, alleviates cerebral edema, decreases neuronal loss, improves neurological deficits and enhances long-term functional outcomes in transient cerebral ischemia models. Pseudoginsenoside F11 antagonizes Methamphetamine-induced behavioral deficits, dopamine level reduction and neurotoxicity without altering the baseline behaviors of normal mice. Pseudoginsenoside F11 can be used in studies related to Alzheimer's disease, transient cerebral ischemic injury and Methamphetamine-induced neurotoxicity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-107665
CAS No.: 62645-28-7
Ro 106-9920 is an orally active NF-κB inhibitor. Ro 106-9920 prevents ubiquitination of IκBα, blocks nuclear translocation of NF-κB, and inhibits NF-κB activation. Ro 106-9920 suppresses TNF-α-induced tissue factor expression and procoagulant activity, enhances TNF-α-mediated cytotoxicity against cancer cells, and eliminates the formation of neutrophil extracellular traps. Ro 106-9920 inhibits NLRP3 inflammasome activation, reduces inflammatory cytokine secretion, decreases myeloperoxidase activity, attenuates renal cell apoptosis, and improves renal function. Ro 106-9920 blocks ANG II (Angiotensin II human) (HY-13948)-induced nuclear localization of p65, internalization of AT1A receptor, colocalization of β-arrestin-2, and expression of COX-2, and alters the formation of β-arrestin endosomes. Ro 106-9920 can be used in research related to non-small cell lung cancer, acute kidney injury, diabetes mellitus, and osteoporosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-139566
CAS No.: 100502-66-7
Purity:  ≥95.0%
Synonyms: 3-Nitroxypropanol; 3-NOP
Target:  

Bacterial

Research Areas:  

Others

Abrucomstat (3-Nitroxypropanol) is an orally active methyl coenzyme M reductase inhibitor. Abrucomstat decreases ruminal methanogenesis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P0251
CAS No.: 60482-95-3
Target:  

Neurotensin Receptor

Research Areas:  

Neurological Disease

Neurotensin (8-13) is an active fragment of Neurotensin. Neurotensin(8-13) results in a decrease in cell-surface NT1 receptors (NTR1) density.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0261
CAS No.: 67979-25-3
Aurantio-obtusin is a anthraquinone compound that can be extracted from cassia seed. Aurantio-obtusin has the effects of decreasing blood pressure, decreasing blood lipids and anti-inflammatory.Aurantio-obtusin is an orally active vasodilator. Aurantio-obtusin ameliorates hepatic steatosis through AMPK/ autophagy- and AMPK/TFEB mediated inhibition of lipid accumulation .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-114189
CAS No.: 790186-68-4
Purity:  99.94%
Synonyms: UNC10225170
Target:  

MEK

Research Areas:  

Cancer

GW284543 (UNC10225170) is a selective MEK5 inhibitor. GW284543 reduces pERK5, and decreases endogenous MYC protein .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-162706
CAS No.: 2519823-37-9
Target:  

PROTACs CDK

Research Areas:  

Cancer

BSJ-5-63 is a potent CDK12, CDK7, CDK9 PROTAC degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-139324
CAS No.: 68341-14-0
Purity:  ≥95.0%
Target:  

GSK-3 Amyloid-β

Research Areas:  

Neurological Disease Cancer

Cu(II)GTSM, a cell-permeable Cu-complex, significantly inhibits GSK3β. Cu(II)GTSM inhibits Amyloid-β oligomers (AβOs) and decreases tau phosphorylation. Cu(II)GTSM also decreases the abundance of Amyloid-β trimers. Cu(II)GTSM is a potential anticancer and antimicrobial agent .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-103372
CAS No.: 685506-42-7
Purity:  99.24%
Target:  

Lipase

Research Areas:  

Cardiovascular Disease

GSK264220A is a potent endothelial lipase inhibitor with IC50 of 16 nM. GSK264220A has the potential to decrease the risk of cardiovascular disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B2009
CAS No.: 101463-69-8
Research Areas:  

Others

Flufenoxuron is a chitin synthesis inhibitor that is used as a benzoylurea insecticide. Flufenoxuron decreases chitin synthesis, molting, and egg hatching, preventing development in insects .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1494
CAS No.: 57468-17-4
Target:  

Neurokinin Receptor

Research Areas:  

Neurological Disease

Substance P (1-9) is nonapeptide, which decreases the inactivation of substance P by the guinea-pig ileum and urinary bladder.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-121118
CAS No.: 467-77-6
Purity:  99.23%
Coronaridine, an iboga type alkaloid, inhibits the wnt signaling pathway by decreasing β-catenin expression .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B1132
CAS No.: 3485-62-9
Synonyms: Ro 2-3773
Target:  

mAChR

Research Areas:  

Neurological Disease

Clidinium bromide is a quaternary amine antimuscarinic agent. Clidinium bromide may help symptoms of cramping and abdominal/stomach pain by decreasing stomach acid, and slowing the intestines in vivo .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P5521
CAS No.: 3033299-76-9
Target:  

Inhibitory Antibodies

Research Areas:  

Cardiovascular Disease

mLR12 is a Trem1 inhibitory peptide. mLR12 decreases aortic rupture rate in BAPN-induced Thoracic aortic aneurysm and dissection (TAAD) mice model .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-130321
CAS No.: 6919-91-1
Purity:  ≥98.0%
Lauroyl-L-carnitine chloride is an orally active metabolite. Lauroyl-L-carnitine chloride significantly reverses the decrease in its target gene IL-10. Lauroyl-L-carnitine chloride alleviates Crohn' s-like colitis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0259
CAS No.: 26807-65-8
Target:  

Potassium Channel

Research Areas:  

Cardiovascular Disease

Indapamide is an orally active sulphonamide diuretic agent, that can reduce blood pressure by decreasing vascular reactivity and peripheral vascular resistance. Indapamide is also can reduce left ventricular hypertrophy .
loading...
    loading...